Birth cohort screening for chronic hepatitis during colonoscopy appointments

American Journal of Gastroenterology

Volumn 108, Issue 6, 2013, Pages 981-989

  Sears, Dawn M ^a,b   Cohen, Dan C ^a,b   Ackerman, Kimberly ^a,b   Ma, Jessica E ^a,b   Song, Juhee ^a,b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; COLONOSCOPY; FEMALE; HEPATITIS A; HEPATITIS B; HUMAN; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SCREENING; SELF REPORT; VIRUS DETECTION;

AGED; COLONOSCOPY; FEMALE; HEPATITIS A; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES; RISK FACTORS; UNITED STATES;

EID: 84878930046     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.50     Document Type: Article

References (40)

1. Wasley A, Kruszon-Moran D, Kuhnert W et al. Th e prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010 ; 202 : 192-201.
2. Armstrong GL, Wasley A, Simard EP et al. Th e prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006 ; 144 : 705-14. (Pubitemid 46780630)
3. Rein DB, Smith BD, Wittenborn JS et al. Th e cost-eff ectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med 2012 ; 156 : 263-70.
4. Rein DB, Wittenborn JS, Weinbaum CM et al. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011 ; 43 : 66-72.
5. Ly KN, Xing J, Klevens RM et al. Th e increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012 ; 156 : 271-8.
6. Sutton AJ, Edmunds WJ, Sweeting MJ et al. Th e cost eff ectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. J Viral Hepat 2008 ; 15 : 797-808.
7. Sutton AJ, Edmunds WJ, Gill ON. Estimating the cost-eff ectiveness of detecting cases of chronic hepatitis C infection on reception into prison. BMC Public Health 2006 ; 6 : 170.
8. Gunn RA, Lee MA, Callahan DB et al. Integrating hepatitis, STD, and HIV services into a drug rehabilitation program. Am J Prev Med 2005 ; 29 : 27-33. (Pubitemid 40825079)
9. Gilbert LK, Bulger J, Scanlon K et al. Integrating hepatitis B prevention into sexually transmitted disease services: US sexually transmitted disease program and clinic trends-1997 and 2001. Sex Transm Dis 2005 ; 32 : 346-50. (Pubitemid 40727178)
10. Castelnuovo E, Th ompson-Coon J, Pitt M et al. Th e cost-eff ectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess 2006 ; 10 : 1-93.
11. Honeycutt AA, Harris JL, Khavjou O et al. Th e costs and impacts of testing for hepatitis C virus antibody in public STD clinics. Public Health Rep 2007 ; 122 (Suppl 2) : 55-62. (Pubitemid 47443833)
12. Arase Y, Suzuki F, Suzuki Y et al. Side eff ects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. Intern Med 2007 ; 46 : 1827-32. (Pubitemid 350200167)
13. Iwasaki Y, Iked H, Araki Y et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006 ; 43 : 54-63. (Pubitemid 43733592)
14. Th abut D, Le Calvez S, Th ibault V et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006 ; 101 : 1260-7. (Pubitemid 43829992)
15. Dalton CB, Haddix A, Hoff man RE et al. Th e cost of a food-borne outbreak of hepatitis A in Denver, Colo. Arch Intern Med 1996 ; 156 : 1013-6. (Pubitemid 26149128)
16. Bell BP, Kruszon-Moran D, Shapiro CN et al. Hepatitis A virus infection in the United States: serologic results from the Th ird National Health and Nutrition Examination Survey. Vaccine 2005 ; 23 : 5798-806. (Pubitemid 41668887)
17. Lu PJ, Byrd KK, Murphy TV et al. Hepatitis B vaccination coverage among high-risk adults 18-49 years, US 2009. Vaccine 2011 ; 29 : 7049-57.
18. Euler GL, Lu P, Singleton JA. Vaccination coverage among US adults: National Immunization Survey 2007. 2008 CDC accessed 26 March 2008. http://www. cdc.gov/vaccines/stats-surv/nis/downloads/nis-adult-summer-2007.pdf.
19. Lu PJ, Euler GL, Hennessey KA et al. Hepatitis A vaccination coverage among adults aged 18-49 years in the United States. Vaccine 2009 ; 27 : 1301-5.
20. Qaseem A, Denberg TD, Hopkins Jr RH et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med 2012 ; 156 : 378-86.
21. Nakamura J, Terajima K, Aoyagi Y et al. Cost-eff ectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Exp Med 2008 ; 215 : 33-42. (Pubitemid 351791266)
22. McGarry LJ, Pawar VS, Panchmatia HR et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012 ; 55 : 1344-55.
23. US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: recommendation statement. Ann Intern Med 2004 ; 140 : 462-4.
24. Piton A, Poynard T, Imbert-Bismut F et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the defi nition of normal values, for selection of blood donors, and for patients with chronic hepatitis C MULTIVIRC Group. Hepatology 1998 ; 27 : 1213-9. (Pubitemid 28227846)
25. Ferrante JM, Winston DG, Chen PH et al. Family physicians ' knowledge and screening of chronic hepatitis and liver cancer. Fam Med 2008 ; 40 : 345-61.
26. Coppola AG, Karakousis PC, Metz DC et al. Hepatitis C knowledge among primary care residents: is our teaching adequate for the times? Am J Gastroenterol 2004 ; 99 : 1720-5. (Pubitemid 39237499)
27. Mostert MC, Richardus JH, de Man RA. Referral of chronic hepatitis B patients from primary to specialist care: making a simple guideline work. J Hepatol 2004 ; 41 : 1026-30. (Pubitemid 39575671)
28. Groom H, Dieperink E, Nelson DB et al. Outcomes of a hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol 2008 ; 42 : 97-106.
29. Han B, Gfroerer J, Colliver J. An examination of trends in illicit drug use among adults aged 50 to 59 in the United States. Offi ce of Applied Studies 2009. http://www.samhsa.gov.
30. Davis KL, Mitra D, Medjedovic J et al. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011 ; 45 : e17-24.
31. Kim WR. Th e burden of hepatitis C in the United States. Hepatology 2002 ; 36 : S30-4.
32. Wong JB, Koff RS, Tine F et al. Cost-eff ectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995 ; 122 : 664-75.
33. Federico CA, Hsu PC, Krajden M et al. Patient time costs and out-of-pocket costs in hepatitis C. Liver Int 2012 ; 32 : 815-25.
34. Khoury AC, Klimack WK, Wallace C et al. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat 2011 ; 19 : 153-60.
35. Berge JJ, Drennan DP, Jacobs RJ et al. Th e cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 2000 ; 31 : 469-73. (Pubitemid 30078614)
36. Sypsa V, Hadjipaschali E, Hatzakis A. Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees. Eur J Epidemiol 2001 ; 17 : 721-8. (Pubitemid 34602338)
37. Sroczynski G, Esteban E, Conrads-Frank A et al. Long-term eff ectiveness and cost-eff ectiveness of screening for hepatitis C virus infection. Euro J Public Health 2009 ; 19 : 245-53.
38. Liu S, Smith BD, Wittenborn JS et al. New protease inhibitors for the treatment of chronic hepatitis C: a cost-eff ectiveness analysis. Ann Intern Med 2012 ; 156 : 279-90.
39. Van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response. All-cause mortality among patients with chronic hepatitis C and advanced hepatic fi brosis. JAMA 2012 ; 308 : 2584-93.
40. Zauber AG, Winawer SJ, OBrien MJ et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012 ; 366 : 687-96.